Cargando…

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients

BACKGROUND: Thrombosis in COVID-19 worsens mortality. In our study, we sought to investigate how the dose and type of anticoagulation (AC) can influence patient outcomes. METHODS: This is a single-center retrospective analysis of critically ill intubated patients with COVID-19, comparing low-molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: Volteas, Panagiotis, Drakos, Panagiotis, Alkadaa, Leor N., Cleri, Nathaniel A., Asencio, Anthony A., Oganov, Anthony, Giannopoulos, Stefanos, Saadon, Jordan R., Mikell, Charles B., Rubano, Jerry A., Labropoulos, Nicos, Tassiopoulos, Apostolos K., Mofakham, Sima, Bannazadeh, Mohsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212478/
https://www.ncbi.nlm.nih.gov/pubmed/35716998
http://dx.doi.org/10.1016/j.jvsv.2022.04.019
_version_ 1784730603930779648
author Volteas, Panagiotis
Drakos, Panagiotis
Alkadaa, Leor N.
Cleri, Nathaniel A.
Asencio, Anthony A.
Oganov, Anthony
Giannopoulos, Stefanos
Saadon, Jordan R.
Mikell, Charles B.
Rubano, Jerry A.
Labropoulos, Nicos
Tassiopoulos, Apostolos K.
Mofakham, Sima
Bannazadeh, Mohsen
author_facet Volteas, Panagiotis
Drakos, Panagiotis
Alkadaa, Leor N.
Cleri, Nathaniel A.
Asencio, Anthony A.
Oganov, Anthony
Giannopoulos, Stefanos
Saadon, Jordan R.
Mikell, Charles B.
Rubano, Jerry A.
Labropoulos, Nicos
Tassiopoulos, Apostolos K.
Mofakham, Sima
Bannazadeh, Mohsen
author_sort Volteas, Panagiotis
collection PubMed
description BACKGROUND: Thrombosis in COVID-19 worsens mortality. In our study, we sought to investigate how the dose and type of anticoagulation (AC) can influence patient outcomes. METHODS: This is a single-center retrospective analysis of critically ill intubated patients with COVID-19, comparing low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) at therapeutic and prophylactic doses. Of 218 patients, 135 received LMWH (70 prophylactic, 65 therapeutic) and 83 UFH (11 prophylactic, 72 therapeutic). The primary outcome was mortality. Secondary outcomes were thromboembolic complications confirmed on imaging and major bleeding complications. Cox proportional-hazards regression models were used to determine whether the type and dose of AC were independent predictors of survival. We performed Kaplan-Meier survival analysis to compare the cumulative survivals. RESULTS: Overall, therapeutic AC, with either LMWH (65% vs 79%, P = .09) or UFH (32% vs 46%, P = .73), conveyed no survival benefit over prophylactic AC. UFH was associated with a higher mortality rate than LMWH (66% vs 28%, P = .001), which was also evident in the multivariable analysis (LMWH vs UFH mortality, hazard ratio: 0.47, P = .001) and in the Kaplan-Meier survival analysis. Thrombotic and bleeding complications did not depend on the AC type (prophylactic LMWH vs UFH: thrombosis P = .49, bleeding P = .075; therapeutic LMWH vs UFH: thrombosis P = .5, bleeding P = .17). When comparing prophylactic with therapeutic AC, the rate of both thrombotic and bleeding complications was higher with the use of LMWH compared with UFH. In addition, transfusion requirements were significantly higher with both therapeutic LMWH and UFH. CONCLUSIONS: Among intubated critically ill COVID-19 intensive care unit patients, therapeutic AC, with either LMWH or UFH, conveyed no survival benefit over prophylactic AC. AC with LMWH was associated with higher cumulative survival compared with AC with UFH.
format Online
Article
Text
id pubmed-9212478
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc
record_format MEDLINE/PubMed
spelling pubmed-92124782022-06-22 Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients Volteas, Panagiotis Drakos, Panagiotis Alkadaa, Leor N. Cleri, Nathaniel A. Asencio, Anthony A. Oganov, Anthony Giannopoulos, Stefanos Saadon, Jordan R. Mikell, Charles B. Rubano, Jerry A. Labropoulos, Nicos Tassiopoulos, Apostolos K. Mofakham, Sima Bannazadeh, Mohsen J Vasc Surg Venous Lymphat Disord Clinical Research Study BACKGROUND: Thrombosis in COVID-19 worsens mortality. In our study, we sought to investigate how the dose and type of anticoagulation (AC) can influence patient outcomes. METHODS: This is a single-center retrospective analysis of critically ill intubated patients with COVID-19, comparing low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) at therapeutic and prophylactic doses. Of 218 patients, 135 received LMWH (70 prophylactic, 65 therapeutic) and 83 UFH (11 prophylactic, 72 therapeutic). The primary outcome was mortality. Secondary outcomes were thromboembolic complications confirmed on imaging and major bleeding complications. Cox proportional-hazards regression models were used to determine whether the type and dose of AC were independent predictors of survival. We performed Kaplan-Meier survival analysis to compare the cumulative survivals. RESULTS: Overall, therapeutic AC, with either LMWH (65% vs 79%, P = .09) or UFH (32% vs 46%, P = .73), conveyed no survival benefit over prophylactic AC. UFH was associated with a higher mortality rate than LMWH (66% vs 28%, P = .001), which was also evident in the multivariable analysis (LMWH vs UFH mortality, hazard ratio: 0.47, P = .001) and in the Kaplan-Meier survival analysis. Thrombotic and bleeding complications did not depend on the AC type (prophylactic LMWH vs UFH: thrombosis P = .49, bleeding P = .075; therapeutic LMWH vs UFH: thrombosis P = .5, bleeding P = .17). When comparing prophylactic with therapeutic AC, the rate of both thrombotic and bleeding complications was higher with the use of LMWH compared with UFH. In addition, transfusion requirements were significantly higher with both therapeutic LMWH and UFH. CONCLUSIONS: Among intubated critically ill COVID-19 intensive care unit patients, therapeutic AC, with either LMWH or UFH, conveyed no survival benefit over prophylactic AC. AC with LMWH was associated with higher cumulative survival compared with AC with UFH. Elsevier Inc 2022-09 2022-06-15 /pmc/articles/PMC9212478/ /pubmed/35716998 http://dx.doi.org/10.1016/j.jvsv.2022.04.019 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical Research Study
Volteas, Panagiotis
Drakos, Panagiotis
Alkadaa, Leor N.
Cleri, Nathaniel A.
Asencio, Anthony A.
Oganov, Anthony
Giannopoulos, Stefanos
Saadon, Jordan R.
Mikell, Charles B.
Rubano, Jerry A.
Labropoulos, Nicos
Tassiopoulos, Apostolos K.
Mofakham, Sima
Bannazadeh, Mohsen
Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
title Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
title_full Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
title_fullStr Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
title_full_unstemmed Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
title_short Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
title_sort low-molecular-weight heparin compared with unfractionated heparin in critically ill covid-19 patients
topic Clinical Research Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212478/
https://www.ncbi.nlm.nih.gov/pubmed/35716998
http://dx.doi.org/10.1016/j.jvsv.2022.04.019
work_keys_str_mv AT volteaspanagiotis lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT drakospanagiotis lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT alkadaaleorn lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT clerinathaniela lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT asencioanthonya lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT oganovanthony lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT giannopoulosstefanos lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT saadonjordanr lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT mikellcharlesb lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT rubanojerrya lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT labropoulosnicos lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT tassiopoulosapostolosk lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT mofakhamsima lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients
AT bannazadehmohsen lowmolecularweightheparincomparedwithunfractionatedheparinincriticallyillcovid19patients